^
Association details:
| Biomarker: | FGFR3 mutation |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | CPL304110 (FGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
550P - Preclinical characterization of CPL304110 as a potential selective inhibitor of fibroblast growth factors 1/2/3 in solid cancers
Published date:
09/14/2020
Excerpt:
CPL304110 showed strong inhibitory effect on FGFR2 (IC50 = 1.44 nM), FGFR1 (4.08 nM) and lower on FGFR3 (10.55 nM)….Cells treated with CPL304110 showed substantial decrease in activation of FGFR-mediated signaling. In the Diversity PLUS panel CPL304110 showed broad antiproliferative and anti-inflammatory impact. In vivo, oral administration of CPL304110 resulted in strong antitumour efficacy in all tested xenograft models.
